Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer
Authors:
- Tímea TőkésTTTímea Tőkés
- Magdolna DankMDMagdolna Dank
- Janina KulkaJKJanina Kulka
- Szabolcs SzakállSSSzabolcs Szakáll
- Zsolt LengyelZLZsolt Lengyel
- 1 January 2015
- journal article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 36 (1) , 28-37
Abstract
The aim of this study was to observe the relationships between different metabolic parameters and clinicopathological features (CPFs) or immunohistochemically defined biological subtypes (IHC-BS) in breast cancer. Eighty-two women (83 lesions, tumour size>15 mm) underwent PET/computed tomography imaging after a core biopsy. Maximum and average standardized uptake values (SUVmax, SUVavg), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) in the primary tumour were calculated and compared with CPFs and IHC-BS. Tumours with oestrogen receptor (ER) positivity were separately investigated in relation to their progesterone receptor (PR) status. Significant correlation was found between all metabolic parameters and high nuclear grade or ER status or IHC-BS. All parameters were higher in PR(-) and triple-negative cases than in PR(+) and non-triple-negative tumours, and the correlation was significant for most of the metabolic parameters (except for SUVavg in the case of PR status and MTV in the case of triple negativity). Significant correlation was found only for SUVmax regarding the human epidermal growth factor receptor 2 (HER2) status. There was moderate correlation between the Ki67 expression and the SUVmax or SUVavg. All metabolic parameters were higher in ER(+)/PR(-)/HER2(-) lesions compared with ER(+)/PR(+)/HER2(-) cancers. However, ER(+)/PR(-)/HER2(+) tumours had lower SUVmax and SUVavg compared with ER(+)/PR(+)/HER2(+) lesions. Our study confirms that the fluorine-18 fluorodeoxyglucose uptake in primary tumour is associated with distinct CPFs or IHC-BS in breast cancer. SUVmax may reflect tumour metabolism more reliably compared with SUVavg, MTV or total lesion glycolysis. Our preliminary results suggest different biological properties in ER(+) tumours with different PR statuses.Keywords
This publication has 24 references indexed in Scilit:
- Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Performance of FDG PET/CT in the Clinical Management of Breast CancerRadiology, 2013
- Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast CancerJNCI: Journal of the National Cancer Institute, 2012
- Increased FDG uptake in breast cancer is associated with prognostic factorsAnnals of Nuclear Medicine, 2012
- Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancerAnnals of Nuclear Medicine, 2011
- Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factorsInternational Journal of Clinical Oncology, 2010
- 18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical AnalysisJournal of Nuclear Medicine, 2010
- 18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in OsteosarcomaJournal of Nuclear Medicine, 2009
- Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion GlycolysisClinical Positron Imaging, 1999